Corporate Governance

Prior to becoming CEO for iBio in March 2020, Mr. Isett played an integral part in reshaping the Company’s strategy and operations in his role as Board Member and Strategic Advisor since April 2019. He was able to contribute his deep management and strategic insights via the consulting firm he founded in 2015, i.e. Advising, LLC, which supported Fortune 500s, institutional investors, biotechs and non-profits alike with M&A, turnarounds, and more. 

Previously, he ran business units for GE, Lonza, and BD, ranging in size from start-up to a half billion in revenues. Notably, he founded BD Advanced Bioprocessing (which sold to ThermoFisher in 2018 for $477M), and Commence Bio, Inc. a cellular immunotherapy company. Mr. Isett received his B.Sc. degree with Honors in Biological Sciences from Drexel University.

Dr. Linda Armstrong has more than 20 years of experience in biopharmaceutical research.  She currently leads the Global Respiratory Development Unit at Novartis. She has served in a range of executive roles across R&D disciplines including Clinical Development, Patient Safety and Medical Affairs, supporting the development of small molecules, biologics and cell and gene therapies. Prior to her current role, she held management positions at the Schering-Plough Research Institute and Pfizer, Inc. Dr. Armstrong received her medical degree from Yale University School of Medicine and her Bachelor’s Degree from Harvard University. She is a trained Pulmonologist and was on the faculty at New York University School of Medicine prior to joining industry.

Since February 2014, Glenn Chang serves as Finance Officer of Singer Vehicle Design, a private company in the business of automotive design and restoration. Mr. Chang served as the Chief Financial Officer of Alma Bank, a New York headquartered bank with over $900 million of assets and 13 branches in the New York City Metropolitan area from late 2012 to February 2014. Before joining Alma, from 1999 to 2012, Mr. Chang served as a founder, Director, Chief Financial Officer and consultant to First American International Bank which was the largest locally owned Chinese American Bank in New York City. Prior to that he spent 20 years at Citibank, N.A as Vice President. Mr. Chang is a retired Certified Public Accountant. Mr. Chang's extensive executive and financial leadership in his current and former positions and his training and experience as a Certified Public Accountant adds vital expertise to our board of directors and our Audit Committee in the form of financial understanding, business perspective and audit expertise. Mr. Chang is qualified as an Audit Committee Financial Expert as defined in Regulation S-K Item 407(d)(5)(ii).

Seymour Flug was Chairman of the Board and CEO of Diners Club International and a Managing Director of Citibank. Prior to joining Citibank, Mr. Flug served as Senior Vice President of Hess Oil Company. Mr. Flug began his career as Certified Public Accountant at Deloitte & Touche, a predecessor to the firm now known as Deloitte. Mr. Flug received his B.B.A from Baruch College. Mr. Flug's experience leading a multinational company and his experience as a certified public accountant allow him to offer us unique perspectives on global business opportunities, best business practices and additional audit expertise. Mr. Flug is qualified as an Audit Committee Financial Expert as defined in Regulation S-K Item 407(d)(5)(ii).

General (Ret.) James T. Hill was the Commander of the 4-Star United States Southern Command, reporting directly to the President and Secretary of Defense at the time of his retirement from active duty. As such, he led all U.S. military forces and operations in Central America, South America and the Caribbean, worked directly with U.S. Ambassadors, foreign heads of state, key Washington decision-makers, foreign senior military and civilian leaders, developing and executing United States policy. His responsibilities included management, development and execution of plans and policy within the organization including programming, communications, manpower, operations, logistics and intelligence. General Hill's deep experience managing and leading large diverse organizations through periods of great change is a key resource.

Robert B. Kay is the Company’s director, founder and former Chief Executive Officer. Previously, Mr. Kay was a founder and senior partner of the New York law firm of Kay Collyer & Boose LLP, with a particular focus on mergers and acquisitions and joint ventures. Mr. Kay received his B.A. from Cornell University's College of Arts & Sciences and his J.D. from New York University Law School. Given his years of service with the Company and his prior experience, we believe that Mr. Kay has an excellent understanding of our business and the global markets in which we operate and those in which we anticipate operating in the future and therefore is able to make valuable contributions to our Board of Directors.

Dr. Alexandra Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Since 2016, she has served as Vice President, Global Specialty R&D, Respiratory & Inflammation Therapeutic Area at Teva Pharmaceuticals, where she leads innovative drug development focused on delivering a broad portfolio of Respiratory and Immunology assets spanning from pre-IND to BLA/NDA filing of biologics to complex drug-device combination products, including advances into the rapidly emerging field of digital health technologies.    

Previously, Dr. Kropotova held several leadership positions at Sanofi, Wyeth, and Pfizer, both in Global R&D and Medical Affairs. Dr. Kropotova’s vision contributed to the filing of several patents and bringing a number of new compounds into R&D. Dr. Kropotova received her MBA from Ohio University Graduate School of Business and her Medical Degree in Internal Medicine from the Vladivostok State Medical University.  She also serves on the Board of the National Alliance of Research Associates Programs.

John D. McKey, Jr. served as counsel at McCarthy, Summers, Bobko, Wood, Sawyer & Perry, P.A. in Stuart, Florida, and was a partner from 1987 through 2003. From 1977 to 1987, Mr. McKey was a partner at Gunster Yoakley in Palm Beach, Florida. Mr. McKey received his B.B.A at the University of Georgia and his J.D. from the University Of Florida College Of Law. Mr. McKey's extensive experience representing private and public companies operating in varied business sectors brings our board insights and acumen to best corporate practices and implementation of strategic and financial plans.

In an executive leadership career spanning more than 20 years, Mr. Schimmelpennink has applied his strategic and functional expertise across corporate development, commercial operations, manufacturing, and R&D to help build and scale a number of global public and private biopharmaceutical businesses. He currently serves as President and CEO of LENZ Therapeutics, a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for presbyopia. Previously, he served as CEO of Pfenex Inc., a NYSEA-listed company which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million (including contingent value rights) in October 2020. Previously, Mr. Schimmelpennink served as CEO of Alvotech Ehf, a global biopharmaceutical company focused on becoming a leader in the biosimilar monoclonal antibody market. Prior to joining Alvotech, he held variety of progressive roles with Pfizer Inc., Hospira, Inc., Synthon BV and Numico NV. Mr. Schimmelpennink holds a Masters in Bioprocess Engineering from the Wageningen University in the Netherlands.

Gary Sender has served as the Chief Financial Officer of Nabriva Therapeutics plc since 2016. Nabriva is a Nasdaq-listed biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Prior to joining Nabriva, he served as CFO and Executive Vice President at Synergy Pharmaceuticals from 2015 to 2016. From 2009 until 2015, Mr. Sender served as Senior Vice President, Finance at Shire Plc., supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Mr. Sender also serves on the board of directors of Schrodinger Inc. and Harmony Biosciences Holdings, Inc. He is the Chairman of both company's Audit Committees. Mr. Sender received his B.S. from Boston University and an M.B.A from Carnegie‑Mellon University.